Hoitt Jason 4

What Happened

• Jason Hoitt, Chief Patient Officer at Stoke Therapeutics, received two equity awards on February 17, 2026: a 72,000-share option award and a 48,000 restricted stock unit (RSU) award. Both grants were reported as derivative awards with a $0.00 reported price (i.e., company awards rather than open‑market purchases). Combined, the awards total 120,000 units.

Key Details

• Transaction date: 2026-02-17 (Form 4 filed 2026-02-19).
• Transaction type/code: A (Grant/Award — derivative).
• Reported price: $0.00 for both awards (no cash paid by insider).
• Vesting for the 72,000 option award: 1/48 of the total vests on March 15, 2026, then 1/48 on each monthly anniversary thereafter (four‑year monthly vesting schedule). (Footnote F1)
• RSU details (48,000): each RSU converts to one share upon settlement; vests 1/4 annually with the first tranche on Feb 15, 2027 (four‑year annual cliff schedule). (Footnotes F2, F3)
• Shares owned after the transaction: not specified in the provided filing details.
• Filing timeliness: filed two days after the transaction date; no late filing flag noted.

Context

• These are standard equity compensation grants (an option award and time‑based RSUs) meant to retain employees; they are not open market purchases or sales and do not indicate immediate buying or selling of stock. The options and RSUs vest over multi‑year schedules, so any economic benefit depends on continued service and future stock performance.